Skip to nav Skip to content
David  Morse

David Morse, PhD

Program: Metabolism and Physiology

Research Program: Molecular Medicine Program


  • Overview


    • Metabolism and Physiology
    • Melanoma & Skin Cancer Center of Excellence
    • Lung Cancer Center of Excellence
    • Molecular Medicine Program
    • Cancer Imaging & Technology Center of Excellence
    • Experimental Therapeutics Program

    Education & Training


    • University of Arizona, PhD - Molecular & Cellular Biology and Cancer Biology
  • Research Interest

    Dr. Morse’s research projects are focused on the identification and validation of cell-surface markers for cancer, discovery of ligands or antibodies specific for binding validated markers, and the development of targeted molecular imaging probes and nanoagents for the detection and treatment of cancer. The ultimate goal of this work is to translate novel probes into the clinic for use in cancer diagnosis and staging, intraoperative margin detection and the targeted delivery of therapy.

  • Publications

    • Abou DS, Zerkel P, Robben J, McLaughlin M, Hazlehurst T, Morse D, Wadas TJ, Pandya DN, Oyama R, Gaehle G, Nickels ML, Thorek DLJ. Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies. Cancer Biother Radiopharm. 2022 Jun.37(5):355-363. Pubmedid: 35695807. Pmcid: PMC9242709.
    • Tafreshi NK, Pandya DN, Tichacek CJ, Budzevich MM, Wang Z, Reff JN, Engelman RW, Boulware DC, Chiappori AA, Strosberg JR, Ji H, Wadas TJ, El-Haddad G, Morse DL. Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2021 Oct.48(11):3408-3421. Pubmedid: 33772332.
    • Divgi C, Carrasquillo JA, Meredith R, Seo Y, Frey EC, Bolch WE, Zimmerman BE, Akabani G, Jacobson DA, Brown B, Davern SM, Hobbs RF, Humm J, Moros EG, Morse D, Papineni R, Zanzonico P, Benedict SH, Sgouros G. Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. Int J Radiat Oncol Biol Phys. 2021 Mar.109(4):905-912. Pubmedid: 33309909. Pmcid: PMC8399328.
    • Roncali E, Capala J, Benedict SH, Akabani G, Bednarz B, Bhadrasain V, Bolch WE, Buchsbaum J, Clarke BN, Coleman N, Dewaraja YK, Frey EC, Ghaly M, Grudzinski J, Hobbs RF, Howell RW, Humm JL, Kunos C, Larson SM, Lin FI, Madsen MT, Mirzadeh S, Morse DL, Pryma DA, Sgouros G, St James S, Wahl RL, Xiao Y, Zanzonico PB, Zukotynski KB. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. J Nucl Med. 2021 Aug.62(8):1133-1139. Pubmedid: 33277396. Pmcid: PMC8833877.
    • Tafreshi NK, Kil H, Pandya DN, Tichacek CJ, Doligalski ML, Budzevich MM, Delva NC, Langsen ML, Vallas JA, Boulware DC, Engelman RW, Gage KL, Moros EG, Wadas TJ, McLaughlin ML, Morse DL. Lipophilicity Determines Routes of Uptake and Clearance, and Toxicity of an Alpha-Particle-Emitting Peptide Receptor Radiotherapy. ACS Pharmacol Transl Sci. 2021 Apr.4(2):953-965. Pubmedid: 33860213. Pmcid: PMC8033749.
    • Tichacek CJ, Tafreshi NK, Kil H, Engelman RW, Doligalski ML, Budzevich MM, Gage KL, McLaughlin ML, Wadas TJ, Silva A, Moros E, Morse DL. Biodistribution and Multicompartment Pharmacokinetic Analysis of a Targeted α Particle Therapy. Mol Pharm. 2020 Nov.17(11):4180-4188. Pubmedid: 32960613.
    • Tafreshi NK, Morse DL, Lee MC. Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer. World J Clin Oncol. 2020 Apr.11(4):169-179. Pubmedid: 32355639. Pmcid: PMC7186233.
    • Tichacek CJ, Budzevich MM, Wadas TJ, Morse DL, Moros EG. A Monte Carlo Method for Determining the Response Relationship between Two Commonly Used Detectors to Indirectly Measure Alpha Particle Radiation Activity. Molecules. 2019 Sep.24(18). Pubmedid: 31546752. Pmcid: PMC6767018.
    • Tafreshi NK, Doligalski ML, Tichacek CJ, Pandya DN, Budzevich MM, El-Haddad G, Khushalani NI, Moros EG, McLaughlin ML, Wadas TJ, Morse DL. Development of Targeted Alpha Particle Therapy for Solid Tumors. Molecules. 2019 Nov.24(23). Pubmedid: 31779154. Pmcid: PMC6930656.
    • Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, Bhatt NB, Kock ND, Messina JL, Ruiz EE, Delva NC, Weaver A, Gibbons WR, Boulware DC, Khushalani NI, El-Haddad G, Triozzi PL, Moros EG, McLaughlin ML, Wadas T, Morse D. Melanocortin 1 Receptor-Targeted α-Particle Therapy for Metastatic Uveal Melanoma. J Nucl Med. 2019 Aug.60(8):1124-1133. Pubmedid: 30733316. Pmcid: PMC6681690.
    • Khabibullin AR, Karolak A, Budzevich MM, McLaughlin ML, Morse DL, Woods LM. Structure and properties of DOTA-chelated radiopharmaceuticals within the 225Ac decay pathway. Medchemcomm. 2018 Jul.9(7):1155-1163. Pubmedid: 30109003. Pmcid: PMC6072494.
    • Karolak A, Estrella VC, Huynh AS, Chen T, Vagner J, Morse DL, Rejniak KA. Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling. Sci Rep. 2018 Feb.8(1):3638. Pubmedid: 29483578. Pmcid: PMC5827036.
    • McFarland C, Yaglom JA, Wojtkowiak JW, Scott J, Morse DL, Sherman MY, Mirny L. The Damaging Effect of Passenger Mutations on Cancer Progression. Cancer Res. 2017 Sep.77(18):4763-4772. Pubmedid: 28536279. Pmcid: PMC5639691.
    • Cohen AS, Khalil FK, Welsh EA, Schabath MB, Enkemann SA, Davis A, Zhou JM, Boulware DC, Kim J, Haura EB, Morse DL. Cell-surface marker discovery for lung cancer. Oncotarget. 2017 Dec.8(69):113373-113402. Pubmedid: 29371917. Pmcid: PMC5768334.
    • Roy J, Putt KS, Coppola D, Leon ME, Khalil FK, Centeno BA, Clark N, Stark VE, Morse DL, Low PS. Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue. Oncotarget. 2016 Mar.7(12):14605-14615. Pubmedid: 26910279. Pmcid: PMC4924738.
    • Khabibullin AR, Karolak A, Budzevich MM, Woods LM, Martinez MV, McLaughlin ML, Morse DL. SU-C-204-03: DFT Calculations of the Stability of DOTA-Based-Radiopharmaceuticals. Med Phys. 2016 Jun.43(6):3314.
    • Huynh AS, Estrella V, Stark VE, Cohen AS, Chen T, Casagni TJ, Josan JS, Lloyd MC, Johnson J, Kim J, Hruby VJ, Vagner J, Morse DL. Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5. Mol Pharm. 2016 Feb.13(2):534-544. Pubmedid: 26713599. Pmcid: PMC4936951.
    • Cohen AS, Patek R, Enkemann SA, Johnson JO, Chen T, Toloza E, Vagner J, Morse DL. Delta-Opioid Receptor (δOR) Targeted Near-Infrared Fluorescent Agent for Imaging of Lung Cancer: Synthesis and Evaluation In Vitro and In Vivo. Bioconjug Chem. 2016 Feb.27(2):427-438. Pubmedid: 26488422. Pmcid: PMC5524213.
    • Sewda K, Coppola D, Enkemann S, Yue B, Kim J, Lopez AS, Wojtkowiak JW, Stark VE, Morse B, Shibata D, Vignesh S, Morse DL. Cell-surface markers for colon adenoma and adenocarcinoma. Oncotarget. 2016 Apr.7(14):17773-17789. Pubmedid: 26894861. Pmcid: PMC4951249.
    • Tafreshi NK, Lloyd MC, Proemsey JB, Bui MM, Kim J, Gillies RJ, Morse DL. Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia. Mol Imaging Biol. 2016 Apr.18(2):219-231. Pubmedid: 26276155. Pmcid: PMC4754166.
    • Damaghi M, Tafreshi NK, Lloyd MC, Sprung R, Estrella V, Wojtkowiak JW, Morse DL, Koomen JM, Bui MM, Gatenby RA, Gillies RJ. Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane. Nat Commun. 2015 Dec.6:8752. Pubmedid: 26658462. Pmcid: PMC4682176.
    • Luddy KA, Robertson-Tessi M, Tafreshi NK, Soliman H, Morse DL. The role of toll-like receptors in colorectal cancer progression: evidence for epithelial to leucocytic transition. Front Immunol. 2014 Oct.5:429. Pubmedid: 25368611. Pmcid: PMC4202790.
    • Tafreshi NK, Lloyd MC, Bui MM, Gillies RJ, Morse DL. Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. Subcell Biochem. 2014 May.75:221-254. Pubmedid: 24146382. Pmcid: PMC4282494.
    • Alleti R, Vagner J, Dehigaspitiya DC, Moberg VE, Elshan NG, Tafreshi NK, Brabez N, Weber CS, Lynch RM, Hruby VJ, Gillies RJ, Morse DL, Mash EA. Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors. Bioorg Med Chem. 2013 Sep.21(17):5029-5038. Pubmedid: 23890524. Pmcid: PMC3773999.
    • Cubitt CL, Menth J, Dawson J, Martinez GV, Foroutan P, Morse DL, Bui MM, Letson GD, Sullivan DM, Reed DR. Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma. 2013 Nov.2013:365723. Pubmedid: 24282374. Pmcid: PMC3824404.
    • Barkey NM, Preihs C, Cornnell HH, Martinez GV, Carie A, Vagner J, Xu L, Lloyd MC, Lynch VM, Hruby VJ, Sessler JL, Sill KN, Gillies RJ, Morse DL. Development and in vivo quantitative magnetic resonance imaging of polymer micelles targeted to the melanocortin 1 receptor. J Med Chem. 2013 Aug.56(16):6330-6338. Pubmedid: 23863078. Pmcid: PMC3807968.
    • Tafreshi NK, Silva A, Estrella VC, McCardle TW, Chen T, Jeune-Smith Y, Lloyd MC, Enkemann SA, Smalley KS, Sondak VK, Vagner J, Morse DL. In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. Mol Pharm. 2013 Aug.10(8):3175-3185. Pubmedid: 23763620. Pmcid: PMC3785103.
    • Martinez GV, Navath S, Sewda K, Rao V, Foroutan P, Alleti R, Moberg VE, Ahad AM, Coppola D, Lloyd MC, Gillies RJ, Morse DL, Mash EA. Demonstration of a sucrose-derived contrast agent for magnetic resonance imaging of the GI tract. Bioorg Med Chem Lett. 2013 Apr.23(7):2061-2064. Pubmedid: 23481651. Pmcid: PMC3602218.
    • Foroutan P, Kreahling JM, Morse DL, Grove O, Lloyd MC, Reed D, Raghavan M, Altiok S, Martinez GV, Gillies RJ. Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy. PLoS One. 2013.8(12):e82875. Pubmedid: 24358232. Pmcid: PMC3865096.
    • Rejniak KA, Estrella V, Chen T, Cohen AS, Lloyd MC, Morse DL. The role of tumor tissue architecture in treatment penetration and efficacy: an integrative study. Front Oncol. 2013.3:111. Pubmedid: 23717812. Pmcid: PMC3650652.
    • Tafreshi NK, Gillies RJ, Morse DL. Molecular imaging of breast cancer lymph node metastasis. Eur J Radiol. 2012 Sep.81 Suppl 1:S160-S161. Pubmedid: 23083574. Pmcid: PMC4529025.
    • Huynh AS, Chung WJ, Cho HI, Moberg VE, Celis E, Morse DL, Vagner J. Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy. J Med Chem. 2012 Nov.55(22):9751-9762. Pubmedid: 23098072. Pmcid: PMC3861893.
    • Wang B, Zhao Q, Barkey NM, Morse DL, Jiang H. Photoacoustic tomography and fluorescence molecular tomography: a comparative study based on indocyanine green. Med Phys. 2012 May.39(5):2512-2517. Pubmedid: 22559621. Pmcid: PMC4108689.
    • Tafreshi NK, Bui MM, Bishop K, Lloyd MC, Enkemann SA, Lopez AS, Abrahams D, Carter WB, Vagner J, Gobmyer SR, Gillies RJ, Morse DL. Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clin Cancer Res. 2012 Jan.18(1):207-219. Pubmedid: 22016510. Pmcid: PMC4130557.
    • Tafreshi NK, Huang X, Moberg VE, Barkey NM, Sondak VK, Tian H, Morse DL, Vagner J. Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. Bioconjug Chem. 2012 Dec.23(12):2451-2459. Pubmedid: 23116461. Pmcid: PMC3563353.
    • Xu L, Josan JS, Vagner J, Caplan MR, Hruby VJ, Mash EA, Lynch RM, Morse DL, Gillies RJ. Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc Natl Acad Sci U S A. 2012 Dec.109(52):21295-21300. Pubmedid: 23236171. Pmcid: PMC3535626.
    • Huynh AS, Abrahams DF, Torres MS, Baldwin MK, Gillies RJ, Morse DL. Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One. 2011 Sep.6(5):e20330. Pubmedid: 21647423. Pmcid: PMC3103544.
    • Rao V, Alleti R, Xu L, Tafreshi NK, Morse DL, Gillies RJ, Mash EA. A sucrose-derived scaffold for multimerization of bioactive peptides. Bioorg Med Chem. 2011 Nov.19(21):6474-6482. Pubmedid: 21940174. Pmcid: PMC3197697.
    • Grobmyer SR, Morse DL, Fletcher B, Gutwein LG, Sharma P, Krishna V, Frost SC, Moudgil BM, Brown SC. The promise of nanotechnology for solving clinical problems in breast cancer. J Surg Oncol. 2011 Mar.103(4):317-325. Pubmedid: 21337565.
    • Tafreshi NK, Enkemann SA, Bui MM, Lloyd MC, Abrahams D, Huynh AS, Kim J, Grobmyer SR, Carter WB, Vagner J, Gillies RJ, Morse DL. A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes. Cancer Res. 2011 Feb.71(3):1050-1059. Pubmedid: 21169406. Pmcid: PMC4130564.
    • Barkey NM, Tafreshi NK, Josan JS, De Silva CR, Sill KN, Hruby VJ, Gillies RJ, Morse DL, Vagner J. Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. J Med Chem. 2011 Dec.54(23):8078-8084. Pubmedid: 22011200. Pmcid: PMC3302579.
    • Martinez GV, Zhang X, García-Martín ML, Morse DL, Woods M, Sherry AD, Gillies RJ. Imaging the extracellular pH of tumors by MRI after injection of a single cocktail of T1 and T2 contrast agents. Nmr Biomed. 2011 Dec.24(10):1380-1391. Pubmedid: 21604311. Pmcid: PMC3693774.
    • Morse DL, Balagurunathan Y, Hostetter G, Trissal M, Tafreshi NK, Burke N, Lloyd M, Enkemann S, Coppola D, Hruby VJ, Gillies RJ, Han H. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem Pharmacol. 2010 Sep.80(5):748-754. Pubmedid: 20510208. Pmcid: PMC2914681.
    • Morse DL, Gillies RJ. Molecular imaging and targeted therapies. Biochem Pharmacol. 2010 Sep.80(5):731-738. Pubmedid: 20399197. Pmcid: PMC2925390.
    • Gillies RJ, Anderson AR, Gatenby RA, Morse DL. The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin Radiol. 2010 Jul.65(7):517-521. Pubmedid: 20541651. Pmcid: PMC4009364.
    • Tafreshi NK, Kumar V, Morse DL, Gatenby RA. Molecular and functional imaging of breast cancer. Cancer Control. 2010 Jul.17(3):143-155. Pubmedid: 20664511.
    • Xu L, Vagner J, Alleti R, Rao V, Jagadish B, Morse DL, Hruby VJ, Gillies RJ, Mash EA. Synthesis and characterization of a Eu-DTPA-PEGO-MSH(4) derivative for evaluation of binding of multivalent molecules to melanocortin receptors. Bioorg Med Chem Lett. 2010 Apr.20(8):2489-2492. Pubmedid: 20304640. Pmcid: PMC2857964.
    • Morse DL, Hostetter G, Balagurunathan Y, Gillies RJ, Han H. Identification of pancreatic cancer-specific cell-surface markers for development of targeting ligands. Methods Mol Biol. 2010.624:195-210. Pubmedid: 20217597. Pmcid: PMC4010309.
    • Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009 Mar.69(6):2260-2268. Pubmedid: 19276390. Pmcid: PMC2834485.
    • Josan JS, Morse DL, Xu L, Trissal M, Baggett B, Davis P, Vagner J, Gillies RJ, Hruby VJ. Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Org Lett. 2009 Jun.11(12):2479-2482. Pubmedid: 19445485. Pmcid: PMC2756606.
    • Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S, Job C, Baggett B, Raghunand N, Gillies RJ. Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. Nmr Biomed. 2009 Jan.22(1):114-127. Pubmedid: 19016452. Pmcid: PMC4130559.
    • Xu L, Vagner J, Josan J, Lynch RM, Morse DL, Baggett B, Han H, Mash EA, Hruby VJ, Gillies RJ. Enhanced targeting with heterobivalent ligands. Mol Cancer Ther. 2009 Aug.8(8):2356-2365. Pubmedid: 19671749. Pmcid: PMC3662534.
    • Balagurunathan Y, Morse DL, Hostetter G, Shanmugam V, Stafford P, Shack S, Pearson J, Trissal M, Demeure MJ, Von Hoff DD, Hruby VJ, Gillies RJ, Han H. Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther. 2008 Sep.7(9):3071-3080. Pubmedid: 18765825. Pmcid: PMC2567866.
    • Vagner J, Xu L, Handl HL, Josan JS, Morse DL, Mash EA, Gillies RJ, Hruby VJ. Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl. 2008.47(9):1685-1688. Pubmedid: 18205159. Pmcid: PMC2716288.
    • Morse D, Galons J, Payne C, Jennings D, Day S, Xia G, Gillies R. MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. Nmr Biomed. 2007 Oct.20(6):602-614. Pubmedid: 17265424.
    • Morse D. Imaging protein-protein interactions in plants and single cells. Proc Natl Acad Sci U S A. 2007 Jun.104(24):9917-9918. Pubmedid: 17551007. Pmcid: PMC1891236.
    • Morse D, Raghunand N, Sadarangani P, Murthi S, Job C, Day S, Howison C, Gillies R. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magn Reson Med. 2007 Aug.58(2):270-280. Pubmedid: 17654590.
    • Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006 Dec.12(24):7271-7278. Pubmedid: 17189398.
    • Morse D, Gray H, Payne C, Gillies R. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther. 2005 Oct.4(10):1495-1504. Pubmedid: 16227398.
    • Morse D, Carroll D, Weberg L, Borgstrom M, Ranger-Moore J, Gillies R. Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem. 2005 Jul.342(1):69-77. Pubmedid: 15958182.
    • Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng. 2005.7:287-326. Pubmedid: 16004573.
    • Baggett B, Roy R, Momen S, Morgan S, Tisi L, Morse D, Gillies RJ. Thermostability of firefly luciferases affects efficiency of detection by in vivo bioluminescence. Mol Imaging. 2004 Oct.3(4):324-332. Pubmedid: 15802049.
    • Ikeda RM, Birkhead GS, DiFerdinando GT, Bornstein DL, Dooley SW, Kubica GP, Morse DL. Nosocomial tuberculosis: an outbreak of a strain resistant to seven drugs. Infect Cont Hosp Ep. 1995 Mar.16(3):152-159. Pubmedid: 7608502.
    • Coles FB, Balzano GJ, Morse DL. An outbreak of influenza A (H3N2) in a well immunized nursing home population. J Am Geriatr Soc. 1992 Jun.40(6):589-592. Pubmedid: 1587976.
    • McNutt LA, Casiano-Colon AE, Coles FB, Morse DL, Menegus M, Groth-Juncker A, Lansky J, Bell K, Schwartz B. Two outbreaks of primarily noninvasive group A streptococcal disease in the same nursing home, New York, 1991. Infect Cont Hosp Ep. 1992 Dec.13(12):748-751. Pubmedid: 1289402.
    • White DJ, Chang HG, Benach JL, Bosler EM, Meldrum SC, Means RG, Debbie JG, Birkhead GS, Morse DL. The geographic spread and temporal increase of the Lyme disease epidemic. Jama. 1991 Sep.266(9):1230-1236. Pubmedid: 1870248.
    • Braun MM, Truman BI, Maguire B, DiFerdinando GT, Wormser G, Broaddus R, Morse DL. Increasing incidence of tuberculosis in a prison inmate population. Association with HIV infection. Jama. 1989 Jan.261(3):393-397. Pubmedid: 2909778.
    • Smith PF, Stricof RL, Shayegani M, Morse DL. Cluster of Haemophilus influenzae type b infections in adults. Jama. 1988 Sep.260(10):1446-1449. Pubmedid: 3261351.
    • Grabau JC, Morse DL. Seropositivity for HIV at alternate sites. Jama. 1988 Dec.260(21):3128. Pubmedid: 3184382.
    • Braun MM, Truman BI, Morse DL, Maguire B, Broaddus R. Tuberculosis and the acquired immunodeficiency syndrome in prisoners. Jama. 1987 Mar.257(11):1471-1472. Pubmedid: 3820454.
    • Morse DL, Hansen RE, Swalbach WG, Redmond SR, Grabau JC. High rate of tuberculin conversion in Indochinese refugees. Jama. 1982 Dec.248(22):2983-2986. Pubmedid: 7143670.
    • Halperin W, Landrigan PJ, Altman R, Iaci AW, Morse DL, Needham LL. Chemical fire at toxic waste disposal plant: epidemiologic study of exposure to smoke and fumes. J Med Soc N J. 1981 Aug.78(9):591-594. Pubmedid: 6790709.
    • Morse DL, Boros L, Findley PA. More on cyanide poisoning from Laetrile. N Engl J Med. 1979 Oct.301(16):892. Pubmedid: 481531.
    • Morse DL, Kominsky JR, Wisseman CL, Landrigan PJ. Occupational exposure to hexachlorocyclopentadiene. How safe is sewage?. Jama. 1979 May.241(20):2177-2179. Pubmedid: 430818.
    • Morse DL, Watson WN, Housworth J, Witherell LE, Landrigan PJ. Exposure of children to lead in drinking water. Am J Public Health. 1979 Jul.69(7):711-712. Pubmedid: 453400. Pmcid: PMC1619117.
    • Morse DL, Harrington JM, Housworth J, Landrigan PJ, Kelter A. Arsenic exposure in multiple environmental media in children near a smelter. Clin Toxicol. 1979 Apr.14(4):389-399. Pubmedid: 466981.
    • Morse DL, Baker EL, Kimbrough RD, Wisseman CL. Propanil-chloracne and methomyl toxicity in workers of a pesticide manufacturing plant. Clin Toxicol. 1979.15(1):13-21. Pubmedid: 159154.
    • Harrington JM, Middaugh JP, Morse DL, Housworth J. A survey of a population exposed to high concentrations of arsenic in well water in Fairbanks, Alaska. Am J Epidemiol. 1978 Nov.108(5):377-385. Pubmedid: 727207.
  • Grants

    • Title: Institutional funds to support DoD MRP award "Translational Studies for Targeted Alpha-Particle Therapy for Rare Melanomas"
      Sponsor: Moffitt Cancer Center
      PI: Morse, D.
    • Title: PET Probes for Senescence Detection in Brain
      Sponsor: Nat Institutes of Health
      PI: Morse, D.
    • Title: Translational studies for targeted alpha-particle therapy for rare melanomas
      Sponsor: US Army
      PI: Morse, D.
    • Title: Orexin receptor agonist discovery for development of colon cancer targeted alpha particle therapy
      Sponsor: Moffitt Cancer Center
      PI: Morse, D., PI: Duckett, D., PI: Ji, M.
    • Title: Engineering Bispecific Nanobodies for Detection of Breast Cancer Nodal Metastasis
      Sponsor: US Army
      PI (Contact): Morse, D.

Find a Researcher Search